Novel compound and use thereof for treating liver cancer
The novel compound NRT-YHD_001, which combines a modified miRNA with a hepatocyte targeting moiety to inhibit Let-7i-5p expression and enhance TSP1 levels, addresses the challenges of immune evasion in liver cancer by boosting macrophage activity, offering a promising treatment for hepatocellular carcinoma.
Patent Information
- Application Number
- PCT/KR2024/005966
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-03
- Filing Date
- 2024-05-02
- Publication Date
- 2024-11-07
AI Technical Summary
Current treatments for liver cancer, particularly hepatocellular carcinoma, have limited effectiveness due to the aggressive nature of the disease and the immune evasion mechanisms employed by cancer cells, such as CD47 expression, which prevents macrophage-mediated phagocytosis, leading to poor survival rates and limited therapeutic options.
A novel compound, NRT-YHD_001, combining a modified miRNA that inhibits Let-7i-5p expression with a hepatocyte targeting moiety, increases TSP1 levels, blocking the CD47-SIRPα interaction, thereby enhancing macrophage phagocytosis activity and inhibiting liver cancer cell growth.
NRT-YHD_001 significantly increases macrophage phagocytosis activity against liver cancer cells, demonstrating potential for effective prevention and treatment of liver cancer by modulating the Let-7i-5p-TSP1 signaling axis and overcoming immune evasion mechanisms.
Smart Images

Figure KR2024005966_07112024_PF_FP_ABST
Abstract
Description
Novel compounds and their use in the treatment of liver cancer The present invention relates to a novel compound comprising a modified miRNA that inhibits the expression of Let-7i-5p and a hepatocyte targeting moiety for use in the prevention or treatment of liver cancer. Liver cancer is the fifth most common cancer worldwide, but it is an aggressive cancer with the third highest mortality rate (Ahn J, Flamm SL Hepatocellular carcinoma Dis Mon 2004;50:556-573). Curative surgery is possible for only 15% to 25% of patients, and most liver cancer patients die relatively quickly from locally advanced or metastatic disease (Roberts LR, Gores GJ Hepatocellular carcinoma: molecular pathways and new therapeutic targets Semin Liver Dis 2005;25:212-225). Hepatitis B virus, hepatitis C virus, and aflatoxin B1 are well known as the main causes of liver cancer. However, the overall survival rate of patients with hepatocellular carcinoma has not significantly improved over the past 20 years, and the mechanisms of hepatocellular carcinoma development and progression are still poorly understood (Bruix J, et al Focus on hepatocellular carcinoma Cancer Cell 2004;5:215-219). Although molecular targeted therapy has been shown to be effective in the treatment of mature hepatocellular carcinoma (Shen YC, Hsu C, Cheng AL Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives J Gastroenterol;45:794-807), it remains unclear how these genetic changes lead to the clinical features observed in individual patients with hepatocellular carcinoma. Histone deacetylases (HDACs) can often be bound to gene promoters by corepressors or multi-protein transcriptional complexes, where they regulate transcription through chromatin modification without directly binding to DNA (Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF Histone deacetylases: unique players in shaping the epigenetic histone code Ann NY Acad Sci 2003;983:84-100) There are 18 encoded human HDACs, which are classified into class I (HDAC 1, 2, 3, and 8), class II (HDAC 4, 5, 6, 7, 9, and 10), class III (SIRT 1-7), and class IV (HDAC11) enzymes (Yang XJ, Seto E The It is known that both histone acetyltransferases and HDACs are involved in cell proliferation, differentiation, and cell cycle regulation (Witt O, Deubzer HE, Milde T, Oehme I HDAC family: What are the cancer relevant targets Cancer Lett 2009;277:8-21) In addition, it has been reported that pathological activation and deregulation of HDACs can cause various diseases such as cancer, immune diseases, and muscular dystrophy (Yang XJ, Seto E HATs and HDACs: from structure, function, and regulation to novel strategies for therapy and prevention Oncogene 2007;26:5310-5318). HDAC6 is a member of the class IIb family of HDACs and acts on microtubules (MTs);
[0004] It acts as a cytoplasmic deacetylase associated with HDAC6 and deacetylates α-tubulin (Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al HDAC6 is a microtubule-associated Mis18α. Nature 2002;417:455-458). Meanwhile, miRNAs are a type of endogenous small RNA (20-25 nucleotides in length) existing within cells. They are derived from non-protein-synthetic DNA and are produced from hairpin-shaped transcripts. miRNAs bind to complementary sequences in the 3'-UTR of target mRNAs, inducing translational inhibition or destabilization of the mRNA, ultimately acting as repressors to suppress protein synthesis of the target mRNA. It is known that a single miRNA can target multiple mRNAs, and an mRNA can also be regulated by multiple miRNAs. Meanwhile, macrophages engulf diseased cells (cancer cells) through phagocytosis, which occurs when the Fc fragment of antibodies binds to Fc receptors on the macrophage membrane. However, tumors can escape attack by immune cells, including macrophages, by subverting the normal immune regulatory machinery. One such mechanism is CD47, a protein expressed on normal cells. CD47 interacts with a macrophage receptor called SIRPα (signal-regulatory protein α), which triggers a "don't eat me" (phagocytosis suppression) signal to macrophages, causing them to leave the normal cells. Similarly, CD47 expression on cancer cells renders them resistant to macrophages even when bound to antibodies. Therefore, although numerous macrophages approach tumors, they cannot act on cancer cells unless the "phagocytosis suppression" signal is turned off. One therapeutic strategy is to block this "phagocytosis suppression" signal using a monoclonal antibody against CD47. The purpose of the present invention is to provide a novel compound. In addition, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating liver cancer. In addition, it is an object of the present invention to provide an immunotherapy pharmaceutical composition for treating CD47-positive liver cancer. In addition, it is an object of the present invention to provide a compound for use in the prevention or treatment of liver cancer. In addition, it is an object of the present invention to provide a method for treating liver cancer. To solve the above problem, the present invention provides a compound of chemical formula 1 in which a nucleic acid molecule that inhibits the expression of Let-7i-5p and a hepatocyte targeting moiety are combined. In addition, the present invention provides a pharmaceutical composition for preventing or treating liver cancer, comprising the compound of the above chemical formula 1 as an active ingredient. In addition, the present invention provides an immunotherapy pharmaceutical composition for treating CD47-positive liver cancer, comprising the compound of the above chemical formula 1 as an active ingredient. In addition, the present invention provides a use of the compound of the above chemical formula 1 for preventing or treating liver cancer. In addition, the present invention provides a method for treating liver cancer, comprising administering a pharmaceutically effective amount of the compound of Chemical Formula 1 to a subject suffering from liver cancer. Compound NRT-YHD_001 of the present invention, which is a modified miRNA that suppresses the expression of Let-7i-5p and a hepatocyte targeting moiety, has chemical formula 1 and inhibits Let-7i-5p in hepatoma cells, thereby increasing TSP1. The increased TSP1 binds to CD47 and prevents interaction with SIRPα of macrophages, thereby significantly increasing macrophage phagocytosis activity against cancer cells. It has an effect of inhibiting the growth of HCC in vivo, and thus can be used for the prevention and treatment of liver cancer. Figure 1 is a diagram showing the synthesis process of miRNA that suppresses the expression of Let-7i-5p. Figure 2 is a diagram showing the synthesis process of NRT-YHD_001. Figure 3 is a diagram showing the LC analysis results of the synthesized NRT-YHD_001 crude product. Figure 4 is a diagram showing the results of LC-TOF analysis of purified NRT-YHD_001. Figure 5 is a diagram showing the inhibition of mRNA expression of let-7i-5p by NRT-YHD_001 in Hep3B cell lines using qRT-PCR. Figure 6 is a diagram showing the stability of NRT-YHD_001 by confirming the amount of NRT-YHD_001 remaining in the cells after treatment with NRT-YHD_001 in Hep3B cells using qPCR. Figure 7 is a diagram showing the promotion of TSP1 (thrombospondin-1) protein expression by NRT-YHD_001 in Hep3B cell lines confirmed by Western blot analysis. Figure 8 is a diagram showing the activation of macrophage phagocytosis of Hep3B cells by NRT-YHD_001 in a Hep3B cell line using an in vitro phagocytosis assay. Figure 9 is a diagram showing the phagocytosis index of macrophages by NRT-YHD_001 in the Hep3B cell line. Figure 10 is a diagram showing the cell growth inhibition effect of NRT-YHD_001 on Hep3B cell lines confirmed by MTT analysis. Figure 11 is a diagram showing the tumor area and its image in Ras-Tg mice treated with a negative control group: Left graph: Tumor area tracking graph for each of the six mice; and Right graph: Tumor area values from six mice combined into one graph. Figure 12 is a diagram showing the tumor area and its image in Ras-Tg mice treated with NRT-YHD_001: Left graph: Tumor area tracking graph for each of the six mice; and Right graph: Tumor area values from six mice combined into one graph. Figure 13 is a diagram showing the liver weight / body weight % of the Ras-Tg mouse group treated with the negative control group and the Ras-Tg mouse group treated with NRT-YHD_001. Figure 14a is a diagram showing the tumor area and its image in saline-treated Ras-Tg mice (n=9). Figure 14b shows the tumor area and its image in Ras-Tg mice (n=9) treated with Sorafenib: PO: Peroral injection. Figure 14c is a diagram showing the tumor area and its image in Ras-Tg mice (n=9) treated with 0.5 mg / kg of NRT-YHD_001: iv: Intravenous injetion. Figure 14d shows the tumor area and its image in Ras-Tg mice (n=9) treated with 1 mg / kg of NRT-YHD_001: iv: Intravenous injetion. Figure 14e is a diagram showing the tumor area and its image in Ras-Tg mice (n=9) treated with 5 mg / kg of NRT-YHD_001: iv: Intravenous injetion. Figure 14f is a diagram showing the liver weight / body weight % of the negative control group (saline administration group), positive control group (Sorafenib administration group), and experimental group (NRT-YHD_001 0.5, 1, or 5 mg / kg administration group). Figure 14g is a graph showing the tumor area values of 9 mice each in the negative control group (saline administration group), positive control group (Sorafenib administration group), and experimental group (NRT-YHD_001 0.5, 1, or 5 mg / kg administration group). Hereinafter, the present invention will be described in detail with reference to the attached drawings and embodiments thereof. However, the following embodiments are provided as examples of the present invention. If a detailed description of a technology or configuration well known to those skilled in the art is judged to unnecessarily obscure the gist of the present invention, such detailed description may be omitted, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the scope of the following claims and equivalents interpreted therefrom. Additionally, the terminology used in this specification is intended to appropriately express preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the customs of the field to which the present invention pertains. Therefore, the definitions of these terms should be determined based on the contents throughout this specification. Throughout this specification, when a part is said to "include" a certain component, unless specifically stated otherwise, this does not mean that other components are excluded, but rather that other components may be included. Throughout this specification, the conventional one-letter and three-letter codes for naturally occurring amino acids are used, as well as generally accepted three-letter codes for other amino acids, such as Aib (α-aminoisobutyric acid) and Sar (N-methylglycine). Furthermore, amino acids referred to herein by abbreviations are described according to the IUPAC-IUB nomenclature as follows: Alanine: A, arginine: R, asparagine: N, aspartic acid: D, cysteine: C, glutamic acid: E, glutamine: Q, glycine: G, histidine: H, isoleucine: I, leucine: L, lysine: K, methionine: M, phenylalanine: F, proline: P, serine: S, threonine: T, tryptophan: W, tyrosine: Y, and valine: V. In one aspect, the present invention relates to a compound comprising a modified nucleic acid molecule targeting Let-7i-5p and a hepatocyte targeting moiety. In one embodiment, the modified nucleic acid molecule may be one in which all bases of a miRNA (SEQ ID NO: 1: AACAGCACAAACUACUACCUCA) that suppresses the expression of Let-7i-5p are modified with 2'-MOE (2'-O-methoxyethyl), and a part or the entire backbone may be modified with phosphorothioate, and preferably, the backbone of the 1st to 4th nucleotides from the 5' end and the 1st to 4th nucleotides from the 3' end among the nucleotides of SEQ ID NO: 1 may be modified with phosphorothioate. In one embodiment, the modified nucleic acid molecule may be represented by the following chemical formula 2: . In one embodiment, the hepatocyte targeting moiety can be GalNAc (N-Acetylgalactosamine). In one embodiment, the compound may be a compound represented by the following chemical formula 1: . In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating liver cancer, comprising the compound of the present invention as an active ingredient. In one embodiment, the compound may be a compound represented by the following chemical formula 1: [Chemical Formula 1] . In one embodiment, the composition of the present invention can inhibit the expression of Let-7i-5p. In one embodiment, the composition of the present invention can inhibit liver cancer cell growth. In one embodiment, the composition of the present invention can increase TSP1 (thrombospondin-1) expression. In one embodiment, the composition of the present invention can increase macrophage phagocytic activity. In one embodiment, the liver cancer may be hepatocellular carcinoma, and may be stage Ⅰ, Ⅱ, Ⅲ, ⅣA or ⅣB hepatocellular carcinoma, and it is more preferable to be stage Ⅲ to Ⅳ hepatocellular carcinoma, which is more difficult to treat than the early stage. In one embodiment, the liver cancer may be a Let-7i-5p high-expression or TSP1 low-expression liver cancer. In one embodiment, the composition of the present invention can occupy the CD47 receptor and interfere with the CD47-SIRPα interaction. In one embodiment, the composition of the present invention can modulate the let-7i-p-TSP1 signaling axis and activate the phagocytosis of macrophages toward HCC cells by converting the CD47-SIRPα interaction between macrophages and HCC to the CD47-TSP1 interaction. In one embodiment, the compounds of the present invention can be used in the form of pharmaceutically acceptable salts, and acid addition salts formed with pharmaceutically acceptable free acids are useful as salts. Acid addition salts are obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, or phosphorous acid, and non-toxic organic acids such as aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates, and alkanedioates, aromatic acids, and aliphatic and aromatic sulfonic acids. These pharmaceutically non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, Contains phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate or mandelate. The acid addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the compound in an excess of an aqueous acid solution and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. Alternatively, the salt can be prepared by evaporating the solvent or excess acid from the mixture and drying it, or by suction filtration of the precipitated salt. In addition, a pharmaceutically acceptable metal salt can be prepared using a base. An alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate. In this case, it is pharmaceutically suitable to prepare a sodium, potassium or calcium salt as the metal salt. In addition, the corresponding silver salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate). The term "nucleic acid molecule" used in the present invention refers to deoxyribonucleotides or ribonucleotides existing in single-stranded or double-stranded form, and includes natural nucleic acid analogs unless otherwise specifically stated (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews, 90:543-584 (1990)). The term "expression suppression" as used in the present invention means causing a decrease in the expression (into mRNA) or translation (into protein) of a target gene, and preferably means that the target gene expression becomes undetectable or exists at an insignificant level. In one aspect, the present invention relates to an immunotherapy pharmaceutical composition for treating CD47-positive liver cancer comprising a compound of formula 1 of the present invention. In one embodiment, the composition of the present invention can inhibit the expression of Let-7i-5p. In one embodiment, the composition of the present invention can inhibit liver cancer cell growth. In one embodiment, the composition of the present invention can increase TSP1 (thrombospondin-1) expression. In one embodiment, the composition of the present invention can increase macrophage phagocytic activity. The pharmaceutical composition of the present invention can be used as a single therapy, but can also be used in combination with other conventional biological therapies, chemotherapy, or radiotherapy, and when such combination therapy is performed, liver cancer can be treated more effectively. When the present invention is used for the prevention and treatment of liver cancer, chemotherapeutic agents that can be used together with the composition include cisplatin, carboplatin, procarbazine, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosourea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide, tamoxifen, taxol, transplatinum, 5-fluorouracil, Examples of radiation therapy that can be used with the composition of the present invention include X-ray irradiation and γ-ray irradiation. In the present invention, the term “prevention” means any act of inhibiting or delaying the occurrence, spread, and recurrence of liver cancer by administering a composition according to the present invention. The therapeutically effective amount of the composition of the present invention may vary depending on various factors, such as the administration method, target site, and patient condition. Therefore, the dosage for human use should be determined as an appropriate amount by considering both safety and efficacy. It is also possible to estimate the amount for human use from the effective amount determined through animal testing. These considerations for determining the effective amount are described, for example, in Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; and E.W. Martin, ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co. The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects. The effective dosage level may be determined based on factors including the patient's health condition, the type and severity of the disease, the activity and sensitivity of the drug, the method of administration, the time of administration, the route and excretion rate, the duration of treatment, drugs used in combination or simultaneously, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by those skilled in the art. The pharmaceutical composition of the present invention may include a carrier, diluent, excipient, or a combination of two or more thereof commonly used in biological preparations. The term "pharmaceutically acceptable" as used herein means that the composition exhibits a property of not being toxic to normal cells or humans exposed to the composition. The carrier is not particularly limited as long as it is suitable for delivering the composition in vivo, and for example, compounds described in Merck Index, 13th ed., Merck & Co. Inc., saline solution, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components may be mixed and used. If necessary, other common additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into a main use form such as an aqueous solution, suspension, or emulsion, pills, capsules, granules, or tablets. Furthermore, it can be preferably formulated according to each disease or ingredient using an appropriate method in the field or the method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990). In one embodiment, the pharmaceutical composition may be in one or more dosage forms selected from the group consisting of oral dosage forms, topical preparations, suppositories, sterile injectable solutions, and sprays. The composition of the present invention may also include a carrier, diluent, excipient, or a combination of two or more thereof commonly used in biological preparations. The pharmaceutically acceptable carrier is not particularly limited as long as it is suitable for in vivo delivery of the composition, and examples thereof include compounds described in Merck Index, 13th ed., Merck & Co. Inc., saline solution, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of one or more of these components. If necessary, other common additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into a main-use dosage form such as an aqueous solution, suspension, or emulsion, or into pills, capsules, granules, or tablets. Furthermore, it can be preferably formulated according to each disease or ingredient using an appropriate method in the field or the method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990). The composition of the present invention may additionally contain one or more active ingredients exhibiting the same or similar function. The composition of the present invention contains the protein in an amount of 0.0001 to 10 wt%, preferably 0.001 to 1 wt%, based on the total weight of the composition. The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable additive. At this time, the pharmaceutically acceptable additive may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, maltose, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, dextrose, sorbitol, and talc. The pharmaceutically acceptable additive according to the present invention is preferably included in the composition in an amount of 0.1 to 90 parts by weight, but is not limited thereto. The composition of the present invention can be administered parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) or orally, depending on the intended method, and the dosage range varies depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease. The daily dosage of the composition according to the present invention is 0.0001 to 10 mg / ml, preferably 0.0001 to 5 mg / ml, and it is more preferable to administer it once or several times a day. Liquid preparations for oral administration of the composition of the present invention include suspensions, solutions, emulsions, syrups, etc., and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. may be included. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, etc. In one aspect, the present invention relates to the use of a modified nucleic acid molecule targeting Let-7i-5p and a compound comprising a hepatocyte targeting moiety for the prevention or treatment of liver cancer. In one embodiment, the compound may be a compound represented by the following chemical formula 1: [Chemical Formula 1] . In addition, the present invention relates to a method for treating liver cancer, comprising administering to a subject suffering from liver cancer a pharmaceutically effective amount of a compound comprising a modified nucleic acid molecule targeting Let-7i-5p and a hepatocyte targeting moiety. In one embodiment, the compound may be a compound represented by the following chemical formula 1: [Chemical Formula 1] . The present invention is described in more detail through the following examples. However, the following examples are intended only to concretize the content of the present invention and are not intended to limit the present invention. Example 1. Production of miRNA that suppresses the expression of Let-7i-5p. 1-1. Solid-phase synthesis and ammonia decomposition Modifying 2'-Ribose to increase resistance to nucleases compared to unmodified RNA, increase stability in the cytoplasm to increase half-life in biological tissues, and strongly bind to complementary RNA to allow more effective degradation of target genes by RNase; And to efficiently bind to target RNA without affecting the activity of RNase, protect it from nucleases by binding to proteins such as albumin in cells and the body, and to prevent the drug from being excreted in urine, all bases of the Let-7i-5p expression-inhibiting miRNA (SEQ ID NO: 1: AACAGCACAAACUACUACCUCA) were modified to 2'-MOE (2'-O-methoxyethyl) to enhance the effect of the drug by replacing the bond between RNA bases with phosphorothioate (2'-MOE rA Phosphoramidite, 2'-MOE rC Phosphoramidite, 2'-MOE rG Phosphoramidite, 2'-MOE rU Phosphoramidite); The backbone of the nucleotides 1 to 4 from the 5' end and the 1 to 4 from the 3' end of the nucleotide of SEQ ID NO: 1 was modified with phosphorothioate, thereby producing an RNA oligo with phosphorothioate-modified bonds (PS bonds) between RNA bases through solid-phase synthesis and ammonolysis (Fig. 1). Specifically, solid-phase assembly for strand preparation was performed on an OligoPilot plus 100 using Unylinker 350 resin (0.875 mmol scale), and it consisted of four chemical reactions in each cycle, including detritylation, coupling, oxidation / sulfurization, and capping.At this time, the DMTr protecting group on the support-bound oligonucleotide was detritylated by acid-mediated removal using a solution of 3% dichloroacetic acid in toluene under UV monitoring control at 350 nm. In addition, coupling was performed using 2.0 eq of a 0.2 M amidite solution dissolved in ACN and 9.0 eq of a 0.6 M ETT solution dissolved in ACN for 22 cycles of recycle coupling (each coupling recycle time: 8 min). In addition, oxidation was performed by contact with 3.0 eq of a 50 mM I2 solution dissolved in Py / H2O (9 / 1, v / v) as an oxidizing agent for 4.0 min. Also, a 0.2 M XH solution dissolved in pyridine was used for sulfurization, and ~6.0 eq of sulfurization was performed with a contact time of 5 min. In addition, 0.5 CV of a 1 / 1 (v / v) mixture of reagents Cap A and Cap B was mixed in series and then transferred to the column with a contact time of 0.5 min and capped. Subsequently, the cyanoethyl protecting group was removed using a 20% DEA solution dissolved in ACN solution with a contact time of 10 min. After the solid-phase synthesis as described above, the column was briefly dried with N2, the obtained solid was suspended in a 28% to 30% NH4OH aqueous solution (87.5 mL), and the reaction mixture was stirred at 40 °C for 16 h. The mixture was filtered, and the solid was washed with water (87.5 mL) (Table 1). Synthetic scaleCrude purityC&D Results(crude solution)0.875 mmol81.27%118 1-2. Purification of miRNA The above solid-phase synthesized miRNA was purified by AEX-HPLC (source 15Q, NaOH+NaCl aq.), and the fractions were desalted and lyophilized to obtain a white solid (Table 2). The modified miRNA (chemical formula 2) manufactured through the above process is shown in Table 3. Crude product amountPurified product amountPurityTotal yield103986 OD79625 OD98.52%35.3% Sequence (5'->3')MW Chemical formulamiRNAeA*eA*eC*eA*eG-eC-eA-eC-eA-eA-eA-eA-eC-eU-eA-eC-eU-eA-eC*eC*eU*eC*eA8495.81C 286 H 416 N 85 O 159 P 21 S8 e: 2'-MOE nucleotides-: PO bond *: PS bond Example 2. Preparation of a nucleic acid molecule compound containing a hepatocyte targeting moiety. 2-1. Solid-phase synthesis and ammonium decomposition of NRT-YHD_001 A compound was synthesized by conjugating a hepatocyte-targeting moiety, GalNAc (N-Acetylgalactosamine), to the modified miRNA produced in Example 1 (WuXi AppTec) (Fig. 2). Specifically, solid-phase assembly for strand preparation was performed on an OligoPilot plus 100 using Unylinker 350 resin (0.35 mmol scale), which consisted of four chemical reactions in each cycle: detritylation, coupling, oxidation / sulfation, and capping. At this time, detritylation was performed by acid-mediated removal of the DMTr protecting group on the support-bound oligonucleotide using a 5% dichloroacetic acid solution in toluene under UV monitoring control at 350 nm. Additionally, coupling was performed with a coupling recycle time of 10 min using 2.0 eq of 0.2 M amidite solution dissolved in ACN and 9.0 eq of 0.6 M ETT solution dissolved in ACN for 1 to 23 nt, and the final amidite was coupled twice using 3.0 eq of 0.25 M amidite and 16.9 eq of 0.6 M ETT. Additionally, oxidation was performed with 3.0 eq of 50 mM I2 solution dissolved in Py / H2O (9 / 1, v / v) as an oxidizing agent for 4.0 min using 3.0 eq of 50 mM I2 solution dissolved in Py / H2O (9 / 1, v / v) for 1 to 23 nt, and in the final oxidation, oxidation was performed with 5.0 eq of oxidizing agent and a contact time of 5.0. Additionally, 0.2 M XH solution dissolved in pyridine was used for sulfurization, and ~6.0 eq of sulfurization was used with a contact time of 5 min. In addition, 0.5 CV of a 1 / 1 (v / v) mixture of reagents Cap A and Cap B was mixed in series and then transferred to a column reactor with a contact time of 0.5 min and capped. After the solid-phase synthesis as described above, the column was briefly dried with N2, the obtained solid was suspended in a 28% to 30% NH4OH aqueous solution (35 mL), and the reaction mixture was stirred at 40°C for 16 h.The mixture was filtered and the solid was washed with water (35 mL) (Table 4). The synthesis of RT-YHD_001 was confirmed by LC (Figure 3). Synthetic scaleC&D Results(crude solution)Crude purity0.35 mmol112 OD / umol63.8% 2-2. Purification of NRT-YHD_001 The above solid-phase synthesized crude product was purified by AEX-HPLC (source 15Q, NaOH+NaCl aq.), and the fractions were desalted and lyophilized to obtain a white solid (Table 5). The purified compound NRT-YHD_001 was confirmed by LC-TOF (Fig. 4). In addition, the compound NRT-YHD_001 (chemical formula 1), which contains a hepatocyte-targeting moiety in a nucleic acid molecule that suppresses the expression of Let-7i-5p manufactured through the above process, is shown in Table 6. Crude product amountPurified product amountPurityTotal yield42900 OD13860 OD90.56%780 mg by weight 12.4% Sequence (5'->3')MWFormulaNRT-YHD_001GalNAc-eA*eA*eC*eA*eG-eC-eA-eC-eA-eA-eA-eC-eU-eA-eC-eU-eA-eC*eC*eU*eC*eA10537.7C 363 H 556 N 91 O 207 P 25 S8 e: 2'-MOE nucleotide-: PO bond *: PS combination Experimental Example 1. Inhibitory Effect of Let-7i-5p Expression To confirm the inhibition of let-7i-5p mRNA expression by NRT-YHD_001 in the Hep3B cell line, a hepatocellular carcinoma cell line, total RNA of the cell line was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA), and cDNA was synthesized using micscipt II RT kit (Qiagen, Manchester, UK) and qRT-PCR was performed using SensiFASTTM SYBR NoROX Kit (Bioline, London, UK). The amount of NRT-YHD_001 remaining in the cells was confirmed by qPCR to confirm the stability of NRT-YHD_001. In addition, we confirmed through Western blot analysis whether the expression of TSP1 (thrombospondin-1), a target protein of let-7i-5p and involved in the regulation of macrophage phagocytosis, was changed by NRT-YHD_001. As a result, the expression of let-7i-5p was suppressed by NRT-YHD_001 treatment (Fig. 5), and residual NRT-YHD_001 was confirmed in the experimental group treated with NRT-YHD_001 (Fig. 6). In addition, the results of Western blot analysis showed that the expression level of TSP1 protein within cells increased by NRT-YHD_001 treatment compared to the control group (Fig. 7). Experimental Example 2. Effect of regulating macrophage phagocytosis To determine whether NRT-YHD_001 treatment occupies the CD47 receptor, thereby disrupting the CD47-SIRPα interaction in the Let-7i-5p-TSP1 network, thereby allowing macrophages to phagocytose HCC, an in vitro phagocytosis assay was performed. Specifically, Hep3B cells were prepared into single-cell suspensions and labeled with CFSE (abcam, Cambridge, UK). Peritoneal macrophages were then obtained from C57BL / 6 mice and co-cultured with NRT-YHD_001-treated Hep3B cells for 2 hours. The phagocytosis index was calculated by dividing the number of macrophages that engulfed tumor cells by the total number of macrophages. As a result, it was found that the phagocytic activity of macrophages toward Hep3B cells was significantly increased when treated with NRT-YHD_001 (Fig. 8), and the phagocytic index of the experimental group treated with NRT-YHD_001 was found to increase (Fig. 9). Therefore, it can be seen that NRT-YHD_001 activates the phagocytosis of macrophages toward HCC cells by converting the CD47-SIRPα interaction between macrophages and HCC into the CD47-TSP1 interaction. Experimental Example 3. Tumor formation inhibitory effect To determine whether NRT-YHD_001 alters the viability of liver cancer cells, an MTT assay was performed. Specifically, Hep3B cells were seeded in 12-well plates, treated with NRT-YHD_001, and incubated with 0.5 mg / ml of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] solution (Sigma) for 1 hour. The absorbance was measured using a SYNERGY H1 Multilabel plate reader (Bio-Tek, Winooski, VT). As a result, it was found that cell growth of Hep3B cells, a liver cancer cell line, was inhibited 72 hours after treatment with NRT-YHD_001 (Fig. 10). Experimental Example 4. In vivo tumor growth inhibition effect To determine whether NRT-YHD_001 treatment induces tumor suppression effects in vivo, NRT-YHD_001 was injected once a week at 1 mg / kg for 7 weeks after tumors were found in Ras-Tg (H-ras12V homozygous transgenic) male mice that develop HCC at approximately 15 to 18 weeks of age. The tumor areas in the liver were checked and photographed, and the liver weight / body weight % was analyzed for each group. As a result, in the case of the negative control group (NC), the tumor area continuously increased (Figs. 11 and 13), whereas in the experimental group injected with NRT-YHD_001, tumor growth was significantly suppressed (Figs. 12 and 13). Experimental Example 5. In vivo tumor growth inhibition effect according to the concentration of NRT-YHD_001. To determine whether NRT-YHD_001 treatment concentration suppresses tumors in vivo, Ras-Tg male mice, which develop HCC at approximately 15 to 18 weeks of age, were injected with NRT-YHD_001 once a week for 9 weeks at 0.5 mg / kg, 1 mg / kg, or 5 mg / kg after tumors were found. The liver tumor area was confirmed and photographed, and the liver weight / body weight % was analyzed for each group. Sorafenib, currently used for the treatment of liver cancer, was administered orally 5 times a week to the positive control group. As a result, in the negative control group (NC, Normal saline) administered with saline, the tumor area continuously increased (Figs. 14a and g), whereas in the experimental group administered with NRT-YHD_001, tumor growth was significantly suppressed in a dose-dependent manner (Figs. 14c to e, and g). In particular, a significantly superior tumor suppression effect was confirmed compared to that in the positive control group administered with Sorafenib, a conventional liver cancer treatment agent (Figs. 14b and g).
Claims
1. A compound represented by the following chemical formula 1: [Chemical Formula 1] .
2. A compound according to claim 1, which specifically inhibits the expression of Let-7i-5p in liver cells.
3. A compound according to claim 1, which increases TSP1 (thrombospondin-1) expression.
4. A compound that increases macrophage phagocytic activity in claim 1.
5. A pharmaceutical composition for preventing or treating liver cancer, comprising the compound of paragraph 1 as an active ingredient.
6. A pharmaceutical composition for preventing or treating liver cancer, which suppresses the expression of Let-7i-5p in paragraph 5.
7. A pharmaceutical composition for preventing or treating liver cancer, which increases TSP1 expression in claim 5.
8. A pharmaceutical composition for preventing or treating liver cancer, which increases macrophage phagocytic activity in claim 5.
9. A pharmaceutical composition for preventing or treating liver cancer, wherein the liver cancer in paragraph 5 is hepatocellular carcinoma.
10. A pharmaceutical composition for preventing or treating liver cancer, wherein the liver cancer in paragraph 5 is Let-7i-5p high-expression or TSP1 low-expression liver cancer.
11. A pharmaceutical composition for the treatment of CD47-positive liver cancer, comprising the compound of paragraph 1 as an active ingredient.
12. A pharmaceutical composition for the treatment of CD47-positive liver cancer, which suppresses the expression of Let-7i-5p in claim 11.
13. A pharmaceutical composition for the treatment of CD47-positive liver cancer, which increases TSP1 expression, according to claim 11.
14. A pharmaceutical composition for treating CD47-positive liver cancer, which increases macrophage phagocytic activity, according to claim 11.
15. Use of the compound of paragraph 1 for the prevention or treatment of liver cancer.
16. A method for treating liver cancer, comprising administering a pharmaceutically effective amount of the compound of paragraph 1 to a subject suffering from liver cancer.
Citation Information
Patent Citations
Delivery system for preventing or treating of liver cancer comprising modified RT-let7 as an active ingredient
KR102428121B1
Galnac phosphoramidites, nucleic acid conjugates thereof and their use
WO2016055601A1
Cited By
Composition for prevention or treatment of liver cancer, comprising modified rt-let7 as active ingredient
EP4372087A4
